by The ebola vaccine market consists of vaccines developed to provide protection against the Ebola virus. The ebola virus causes a severe hemorrhagic fever in humans known as Ebola virus disease or Ebola hemorrhagic fever. Ebola vaccines induce active immunity against the Ebola virus by mimicking an Ebola viral infection, but do not cause disease. Several candidate vaccines are in different stages of clinical trials aimed at prevention as well as post-exposure prophylaxis.
The Global Ebola Vaccine Market is estimated to be valued at Us$ 6.72 Bn in 2024 and is expected to exhibit a CAGR Of 9.4% over the forecast period 2024 To 2030.
Key Takeaways
Key players operating in the Ebola Vaccine Market are 10x Genomics, Akoya Bioscience Inc., Biognosys AG, BioSpyder Technologies, Bio-Techne, Bruker, Brooks Automation Inc., Danaher Corporation, and Diagenode.
The key opportunities in the ebola vaccine market include increasing funding for ebola vaccine development from government and private organizations. The market is also expected to be positively impacted by rising awareness about ebola prevention.
The ebola vaccine market is expected to witness high growth in North America, Europe, and Asia Pacific over the forecast period. This can be attributed to rising healthcare expenditure, presence of major players, and increasing investment in vaccine development.
Market drivers
The key drivers fueling the growth of the ebola vaccine market are increasing R&D investments by pharmaceutical companies and research organizations. Ebola outbreaks in Africa have raised concerns regarding the need for preventive vaccines. This has accelerated research focusing on development of effective and safe ebola vaccines. According to statistics, over US$ 500 million in funds were directed towards ebola vaccine R&D from 2014-2016. In addition, initiatives like EBODAC (Ebola Diseases Treatment and Vaccine) by the U.S. Department of Defense are aiding vaccine development efforts through public-private partnerships.
PEST Analysis
Political: Government bodies and policymakers acknowledge Ebola as a threat and support funding for research and production of vaccines. Strict regulations are in place for safety and efficacy of any vaccine.
Economic: Financing remains a challenge for research and development of Ebola vaccines due to high costs involved and low commercial incentives. International aid helps overcome this issue to an extent.
Social: Public awareness programs educate people about risks of Ebola infection and need for vaccination. However, social stigma around the disease persists in some communities.
Technological: Advances in vaccine production technologies help accelerate research process. Cell-based and nucleic-acid based platforms show promise for developing highly effective and scalable Ebola vaccines.
In terms of value, North America remains the largest geographical market for Ebola vaccines where the USA contributes significantly owing to continuous research initiatives. The region accounted for over 35% market share in 2024.
Sub-Saharan Africa has emerged as the fastest growing regional market over the forecast period. This is mainly due to occurrence of recurrent Ebola outbreaks in Central and West African countries like Democratic Republic of Congo and Guinea. International efforts aim to ensure availability and accessibility of suitable vaccines in these high-risk regions.
Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
